Paper42318367
Nivolumab-Associated Cardiac Manifestation of Cutaneous T-Cell Lymphoma in a Patient With Concurrent Renal Cell Carcinoma.
Ibrahim M and 6 others. Mayo Clin Proc Innov Qual Outcomes, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Nivolumab-Associated Cardiac Manifestation of Cutaneous T-Cell Lymphoma in a Patient With Concurrent Renal Cell Carcinoma. Papers, record 42318367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42318367
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nivolumab-Associated Cardiac Manifestation of Cutaneous T-Cell Lymphoma in a Patient With Concurrent Renal Cell Carcinoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27269947 | Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27269947 | PubMed |
| 2 | 35784303 | Case Report: Primary Cardiac T-Cell Lymphoma With Complete Atrio-Ventricular Block Diagnosed by Endomyocardial Biopsy. | Front Immunol | 2022 | https://conductscience.org/library/papers/35784303 | PubMed |
| 3 | 32766875 | Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. | Blood | 2020 | https://conductscience.org/library/papers/32766875 | PubMed |
| 4 | 29143824 | PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. | Nature | 2017 | https://conductscience.org/library/papers/29143824 | PubMed |
| 5 | 40940933 | Immunotherapy-Associated Cardiotoxicity: Current Insights and Future Directions for Precision Cardio-Oncology. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40940933 | PubMed |
| 6 | 40606990 | Cardiovascular adverse effects of immunotherapy in cancer: insights and implications. | Front Oncol | 2025 | https://conductscience.org/library/papers/40606990 | PubMed |
| 7 | 35559250 | Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35559250 | PubMed |
| 8 | 10583062 | Cardiac involvement and molecular staging in a fatal case of mycosis fungoides. | Br J Dermatol | 1999 | https://conductscience.org/library/papers/10583062 | PubMed |
| 9 | 32898250 | Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas. | Blood Adv | 2020 | https://conductscience.org/library/papers/32898250 | PubMed |
| 10 | 17950613 | Mycosis fungoides. | Crit Rev Oncol Hematol | 2008 | https://conductscience.org/library/papers/17950613 | PubMed |
| 11 | 8284728 | Cardiogenic shock due to progression of cutaneous T-cell lymphoma. | South Med J | 1994 | https://conductscience.org/library/papers/8284728 | PubMed |
| 12 | 35390769 | Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 | https://conductscience.org/library/papers/35390769 | PubMed |
| 13 | 34477818 | Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. | Blood Adv | 2021 | https://conductscience.org/library/papers/34477818 | PubMed |
| 14 | 33752450 | Clinical features of cardiac lymphoma: an analysis of 37 cases. | J Int Med Res | 2021 | https://conductscience.org/library/papers/33752450 | PubMed |
| 15 | 31532724 | Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/31532724 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| TNFRSF8 | 943 | PubTator's text mining | https://conductscience.org/library/genes/943 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42318367
GET https://conductscience.org/api/papers/v1/42318367/authors